Literature DB >> 8249071

Field application of an ELISA using redefined Leishmania antigens for the detection of visceral leishmaniasis.

E A Okong'o-Odera1, A Wamachi, J M Kagai, J A Kurtzhals, J I Githure, A S Hey, J B Were, D K Koech, E S Mitema, A Kharazmi.   

Abstract

Two soluble antigens from Leishmania donovani of 116 kDa and 70 kDa molecular mass, and a soluble mixture of crude antigens, were used in an enzyme-linked immunosorbent assay (ELISA) for the detection of visceral leishmaniasis (VL) in the field, and compared with the direct agglutination test (DAT). The tests were carried out on 8 VL patients, 34 normal individuals from an area endemic for the disease, and 68 former visceral leishmaniasis patients 1-5 years after treatment. The 70 kDa ELISA and the DAT had a sensitivity and specificity of 100% (95% confidence interval 63-100%), while the 116 kDa ELISA and the soluble crude antigen ELISA were 37.5% (9-76%) and 50% (16-84%) sensitive, respectively. When using ELISA (116 kDa or 70 kDa), 68-69% of sera tested 1-2 years, and 92-94% of sera tested 5 years, after treatment were negative. In contrast, when DAT or ELISA with crude antigen were used, the negativity rate was 31% 1-2 years, and 53% 5 years, after treatment. DAT was therefore not an accurate test for diagnosis in the field. The use of the 70 kDa antigen in ELISA was an accurate alternative to DAT in the detection of VL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249071     DOI: 10.1016/0035-9203(93)90023-j

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  9 in total

1.  Comparison of the indirect immunofluorescent antibody test and the direct agglutination test for serodiagnosis of visceral leishmaniasis in HIV-infected subjects.

Authors:  L Nigro; C Vinci; F Romano; R Russo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-10       Impact factor: 3.267

2.  Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India.

Authors:  M Chatterjee; C L Jaffe; S Sundar; D Basu; S Sen; C Mandal
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 3.  Recent advances in tropical medicine.

Authors:  D N Lockwood; G Pasvol
Journal:  BMJ       Date:  1994-06-11

4.  Detection of Leishmania donovani infection using magnetic beads-based serum peptide profiling by MALDI-TOF MS in mice model.

Authors:  Lixia Li; Jiping Li; Hongtao Jin; Limin Shang; Bo Li; Feng Wei; Quan Liu
Journal:  Parasitol Res       Date:  2011-08-18       Impact factor: 2.289

5.  Evaluation of enzyme-linked immunosorbent assay for diagnosis of post-kala-azar dermal leishmaniasis with crude or recombinant k39 antigen.

Authors:  P Salotra; G Sreenivas; A A Nasim; B V Subba Raju; V Ramesh
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  Proteomic approach for characterization of immunodominant membrane-associated 30- to 36-kiloDalton fraction antigens of Leishmania infantum promastigotes, reacting with sera from Mediterranean visceral leishmaniasis patients.

Authors:  Sayda Kamoun-Essghaier; Ikram Guizani; Jean Marc Strub; Alain Van Dorsselaer; Kamel Mabrouk; Lazhar Ouelhazi; Koussay Dellagi
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

7.  Evaluation of cleaving agents other than trypsin in direct agglutination test for further improving diagnosis of visceral leishmaniasis.

Authors:  A el Harith; S Chowdhury; A al-Masum; S Semião-Santos; E Karim; S el-Safi; I Haque
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

8.  Synthetic peptide-based enzyme-linked immunosorbent assay for serodiagnosis of visceral leishmaniasis.

Authors:  C Fargeas; M Hommel; R Maingon; C Dourado; M Monsigny; R Mayer
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

9.  Systematic review on antigens for serodiagnosis of visceral leishmaniasis, with a focus on East Africa.

Authors:  Vera Kühne; Zahra Rezaei; Paul Pitzinger; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2019-08-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.